We also found that treatment with Compound 1, an NRF2 small molecule activator we reported previously [30], could enhance cell proliferation of these two breast cancer cells compared to these cells transfected with negative control siRNA (siCtrl) only (Figure 3). This evidence concerns the gene NFE2L2 and breast cancer.